Expanded Access Program (EAP) in Saudi Arabia

About Expanded Access Program (EAP)

Structured programs offering access to investigational drugs outside of clinical trials.

How Expanded Access Program (EAP) works in Saudi Arabia

The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.

Patients in Saudi Arabia seeking access under Expanded Access Program (EAP) typically follow this flow: a licensed physician in Saudi Arabia issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in Saudi Arabia

• Physician prescription and clinical-justification letter.
• Patient identification and consent.
• Country-specific NPP/personal-import form.
• Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Expanded Access Program (EAP) in Saudi Arabia